Richard Law
Stock Analyst at Goldman Sachs
(0.84)
# 4,161
Out of 5,140 analysts
73
Total ratings
57.14%
Success rate
-15.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $16.71 | -40.16% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $22.95 | +22.00% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $55.41 | +20.92% | 2 | Jan 12, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $26 → $38 | $26.29 | +44.54% | 7 | Dec 11, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $109.04 | +23.81% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $26.70 | +8.61% | 2 | Oct 30, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $31.31 | +66.08% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $32.29 | -7.09% | 4 | Aug 7, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.68 | -47.18% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.69 | +252.30% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $31 | $26.17 | +18.46% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $33.38 | -10.13% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $24.23 | -54.60% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $31.12 | +51.03% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $54.73 | +15.11% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $70.74 | -47.70% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $14.03 | +441.70% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.12 | +560.38% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $12.60 | +384.13% | 4 | May 8, 2023 |
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $16.71
Upside: -40.16%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $22.95
Upside: +22.00%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $55.41
Upside: +20.92%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $26 → $38
Current: $26.29
Upside: +44.54%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $109.04
Upside: +23.81%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $26.70
Upside: +8.61%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $31.31
Upside: +66.08%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $32.29
Upside: -7.09%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.68
Upside: -47.18%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.69
Upside: +252.30%
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $26.17
Upside: +18.46%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $33.38
Upside: -10.13%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $24.23
Upside: -54.60%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $31.12
Upside: +51.03%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $54.73
Upside: +15.11%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $70.74
Upside: -47.70%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $14.03
Upside: +441.70%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.12
Upside: +560.38%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $12.60
Upside: +384.13%